Wednesday, July 1, 2015

Merck stops distributing combo drug for cholesterol and type 2 diabetes because it didn't sell

Merck stops distributing combo drug for cholesterol and type 2 diabetes because it didn't sell.

Merck stops distributing combo drug for cholesterol and type 2 diabetes because it didn't sell


Pharmaceutical companies have been trying hard to squeeze as much revenue out of every drug they develop, which can mean seeking approval for different ailments or expansion of the groups that might benefit from that same drug.

The theory is that having already done the research and testing, they will expand the consumers of such medicine.

Sometimes it works and sometimes it doesn't.

Merck, for example, said Thursday that it will stop distributing Juvisync, which is a tablet that combines sitagliptin and simvastatin, to pharmacies and wholesalers in the United States and Puerto Rico.

Sitagliptin is the active ingredient in Januvia, which is Merck's top-selling drug and prescribed for type 2 diabetics in the hope that it will lower blood sugar. Simvastatin is medicine meant to lower cholesterol.

There is logic in the hope that the combination would work well and sell. Type 2 diabetes and high cholesterol often occur in the same person. But this did not sell.

"This decision is for business reasons only and is not due to the efficacy or safety profile of Juvisync or the individual components," Merck said in its statement.

Merck's headquarters is in Whitehouse Station, N.J., and it has a big operation in West Point, Montgomery County.

Merck is still remaking its research and development department, under new R&D chief Roger Perlmutter. In July, he said he was looking at products, process and people.

In the Inquirer story at the time, Perlmutter said, "There is going to be focus on the products that matter most. There will be a series of changes that take place to improve efficiency, but there are not going to be big, enormous changes."

Perlmutter reiterated some of those thoughts in an interview with the Wall Street Journal earlier this week. A A link is here.



We encourage respectful comments but reserve the right to delete anything that doesn't contribute to an engaging dialogue.
Help us moderate this thread by flagging comments that violate our guidelines.

Comment policy: comments are intended to be civil, friendly conversations. Please treat other participants with respect and in a way that you would want to be treated. You are responsible for what you say. And please, stay on topic. If you see an objectionable post, please report it to us using the "Report Abuse" option.

Please note that comments are monitored by staff. We reserve the right at all times to remove any information or materials that are unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane, indecent or otherwise objectionable. Personal attacks, especially on other participants, are not permitted. We reserve the right to permanently block any user who violates these terms and conditions.

Additionally comments that are long, have multiple paragraph breaks, include code, or include hyperlinks may not be posted.

Read 0 comments
comments powered by Disqus
About this blog
David Sell blogs about the region's pharmaceutical industry. Follow him on Facebook.

For Portions of this blog may also be found in the Inquirer's Sunday Health Section.

Reach David at

David Sell
Also on
letter icon Newsletter